Theraclone collaborates with strategic development partners to create therapeutically important antibody products. We are actively seeking partners to help us discover, develop and commercialize therapeutics in the setting of oncology and infectious disease. Strategic partnerships can be structured on the basis of disease area(s), collaboration roles, degree of financial risk-sharing, and commercial territory.
For vaccine developers, the I-STAR technology can also be used to assess patients' immune response to new vaccines in the early stages of clinical testing through comprehensive analysis of the B cell repertoire.
- Robust and proven fully human mAb discovery platform
- Demonstrated development capabilities
- Strong Research & Development pipeline in oncology and infectious disease
- Influenza antibody program that has completed Phase 2a demonstrating reduction of viral load and clinical symptoms
To date, we have formed strategic collaborations involving antibodies discovered using our I-STAR technology with Gilead, Pfizer, Zenyaku Kogyo and the International AIDS Vaccine Initiative to discover using novel antibodies for the treatment and prevention of disease.
- In October 2015, Theraclone and MD Anderson launched OncoResponse, an immuno-oncology antibody discovery company to identify therapeutic antibodies against novel targets from immune-oncology treated patients.
- In April 2015, Theraclone and Wellcome Trust initiated a collaboration to identify potential therapeutic antibodies against the Ebola virus utilizing Theraclone’s powerful human memory B-cell interrogation platform.
- In July 2014, Theraclone and Gilead entered into an exclusive license to develop and commercialize products incorporating Theraclone’s broadly neutralizing HIV-antibodies for therapeutic applications in HIV.
- In January 2011, Theraclone and Pfizer initiated an I-STAR collaboration to discover antibodies against up to four undisclosed targets in the areas of infectious disease and cancer. Pfizer has Worldwide licensing rights
- In March 2010, Theraclone and Zenyaku Kogyo Co., Ltd. initiated a collaboration to discover and develop broadly protective antibodies for the treatment of pandemic influenza and severe seasonal influenza. Zenyaku Kogyo has licensing rights in Japan.
- In February 2008, Theraclone and the International AIDS Vaccine Initiative (IAVI) initiated a collaboration to discover HIV-neutralizing antibodies. IAVI has Worldwide rights to develop HIV vaccines based on these antibodies